Insulin Resistance Surge Fueling Growth In The Non-Alcoholic Steatohepatitis Treatment Market Driver: A Major Catalyst in the Evolution of the Non-Alcoholic Steatohepatitis Treatment Market in 2025

Which drivers are expected to have the greatest impact on the over the non-alcoholic steatohepatitis treatment market's growth?
The surge in insulin resistance cases is fueling the expansion of the non-alcoholic steatohepatitis treatment market. Insulin resistance, a condition where cells in muscles, fat, and liver do not adequately respond to insulin and struggle to absorb glucose from the blood, contributes to high blood sugar levels. This condition is often associated with unhealthy lifestyles, excessive sugar intake, and genetic factors. Due to the rise in diabetes and other liver-related problems, the incidence of insulin resistance has surged, leading to a higher demand for non-alcoholic steatohepatitis treatment. For example, in January 2022, a report from the International Diabetes Federation, a global diabetes community based in Belgium, revealed that diabetes affects one in ten individuals between 20-79 years old, or approximately 537 million people. This number is projected to rise to 643 million by 2030 and 783 million by 2045. Additionally, according to the American Cancer Society, a nonprofit cancer advocacy organization based in the US, it is anticipated that new liver cancer cases will increase to 41,630 in 2024, up from 41,210 in 2023. Hence, the escalating prevalence of insulin resistance, driven by various liver diseases and diabetes, is expected to stimulate the non-alcoholic steatohepatitis treatment market.

Get Your Non-Alcoholic Steatohepatitis Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What is the future CAGR of the non-alcoholic steatohepatitis treatment market, and how will it impact industry expansion?
The market size of treatment for non-alcoholic steatohepatitis has seen a significant surge in recent times. It is projected to expand from $2.6 billion in 2024 to $3.6 billion in 2025, recording a compound annual growth rate (CAGR) of 38.5%. Factors like increasing cases of NASH, expanded awareness and diagnosis, changes in lifestyle and the obesity crisis, clinical investigations, healthcare facilities and accessibility, regulatory backing and clinical trials, have contributed to the growth in the historical period.

In the coming years, the market size for non-alcoholic steatohepatitis treatment is anticipated to exponentially grow. It is projected to reach $13.83 billion by 2029 with a compound annual growth rate (CAGR) of 40.0%. Factors contributing to the growth during the forecast period include progress in drug development, heightened awareness about the disease, an upward trend in prevalence and risk factors, plus a shift towards individualized medicine. Major trends predicted for the forecast period consist of a more patient-focused approach, advancements in technology, aimed therapies, changes in the regulatory landscape, and improvements in research.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What are the most significant trends transforming the non-alcoholic steatohepatitis treatment market today?
The rise in the creation of non-alcoholic steatohepatitis (NASH) medicines is a prominent trend in the non-alcoholic steatohepatitis treatment market. Numerous firms are investing in the invention of pioneering drugs for liver disease treatment, which are less prone to side-effects. In May 2022, for example, the U.S. Food and Drug Administration (FDA) granted Pfizer Inc., a renowned American pharmaceutical and biotech organization, a fast-track designation to expedite the development of the non-alcoholic steatohepatitis (NASH) drug, specifically ervogastat and clesacostat. This fast-track designation facilitates Pfizer's experimental combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis, namely ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Which key market segments comprise the non-alcoholic steatohepatitis treatment market and drive its revenue growth?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented -

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

What regions are at the forefront of non-alcoholic steatohepatitis treatment market expansion?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the non-alcoholic steatohepatitis treatment market?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Is Covered In The Non-Alcoholic Steatohepatitis Treatment Global Market Report?

• Market Size Forecast: Examine the non-alcoholic steatohepatitis treatment market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the non-alcoholic steatohepatitis treatment market for a structured understanding.
• Key Players Overview: Analyze major players in the non-alcoholic steatohepatitis treatment market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the non-alcoholic steatohepatitis treatment market.
• Segment Contributions: Evaluate how different segments drive overall growth in the non-alcoholic steatohepatitis treatment market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the non-alcoholic steatohepatitis treatment market.
• Industry Challenges: Identify potential risks and obstacles affecting the non-alcoholic steatohepatitis treatment market.
• Competitive Landscape: Review strategic developments in the non-alcoholic steatohepatitis treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.